Alerta

VALACYCLOVIR AND CELECOXIB IN COMBINATION WITH NIRMATRELVIR AND RITONAVIR FOR THE TREATMENT OF COVID-19

Resumen de: US20250186443A1

0000 The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

MICROWAVE DISINFECTION PROTOCOL OPTIMISED FOR THE DESTRUCTION/ INACTIVATION OF SARS-COV-2 AND H1N1 VIRUSES

Resumen de: WO2023161837A1

The invention concerns a microwave disinfection device ( 2 ) configured to destroy/ inactivate the SARS-CoV-2 and H1N1 viruses and comprising a microwave irradiation section ( 22 ) configured to : irradiate microwave signals that have an incident electric field amplitude not higher than 6 V/m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHz and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.

HUMANIZED ACE2-EXPRESSING TRANSGENIC MOUSE SUSCEPTIBLE TO SARS-COV-2 VIRUS INFECTION AND METHOD FOR PRODUCING SAME

Resumen de: US20260305587A1

The present invention discloses a humanized ACE2-expressing transgenic mouse, which is susceptible to infection by the SARS-CoV-2 virus, obtained through the application of the CRISPR system, and a method for producing the same. The humanized ACE2-expressing transgenic mouse of the present invention reflects symptom severity and mortality patterns according to age, sex, and viral inoculation dose, as observed in human COVID-19 cases, and reproduces the immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain. Therefore, it can be usefully employed for understanding the pathogenic mechanisms of SARS-CoV-2 and for the development of vaccines or therapeutics.

NOVEL BAT INFLUENZA A VIRUS-VECTORED MERS VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

Resumen de: WO2026213490A1

Described herein is a novel bat influenza A virus-based vaccine vector modified by replacing the open reading frame of either bat influenza hemagglutinin or neuraminidase with that of hemagglutinin-esterase-fusion gene from influenza D virus that can infect multiple species including humans and camels. A temperature-sensitive, cold-adapted and attenuated MERS vaccine candidate expressing the clade A MERS-CoV spike S1 was then developed, referred to as Len_S1, using the developed bat influenza vector and demonstrated its safety and immunogenicity. A single-dose intranasal immunization with Len_S1 was able to protect hDPP4 transgenic mice from a lethal MERS-CoV challenge. Notably, two-dose immunization with Len_S1 completely blocked viral replication and lung damage of challenged mice. Len_S1 is a safe and effective MERS vaccine that can induce a comprehensive immune response and provide cross-protection against different clades of MERS-CoVs.

METHODS OF ASSESSING RISK AND TREATING COVID-19

Resumen de: WO2026213157A1

The present disclosure relates to methods of treating coronavirus disease 2019 (COVID-19), methods of assessing risk(s) associated with COVID-19, and methods of preventing long COVID.

ACE2 INHIBITION ASSAY FOR EVALUATION OF VACCINE IMMUNOGENICITY

Resumen de: US20260309709A1

An improved assay to measure immunogenicity of vaccines while overcoming some of the limitations of current biomarkers of immunogenicity is necessary. Disclosed herein is an assay for measuring inhibition of binding between SARS-CoV-2 Spike (S) glycoproteins and hACE2. Also provided herein are methods of using the assay to evaluate the efficacy of COVID-19 vaccines.

PRODUCTION METHOD

Resumen de: US20260306577A1

0000 The invention relates, inter alia, to methods of preparing a garlic oil, garlic oils produced using the method, pharmaceutical compositions comprising the garlic oil and uses of the garlic oil in the treatment of viral infections such as SARS-COV-2 and influenza A. The methods of preparing a garlic oil comprise the steps of: a) processing a portion of a garlic plant to increase its surface area; b) ageing the portion of the garlic plant for at least 18 months to provide an aged garlic, which does not comprise addition of ethanol; and c) separating the garlic oil in the aged garlic. Step c) may be performed using spinning cone distillation or supercritical fluid extraction, at a temperature below 110° C., or such that the pressure (atmospheres) divided by the temperature (degrees Kelvin) is equal to or less than about 0.0026.

ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR

Resumen de: EP4817612A2

0001 Provided is application of a poly ADP ribose polymerase inhibitor or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for the treatment of diseases caused by viruses, wherein the viruses are β-coronavirus viruses. Also provided is application of a compound represented by formula III and/or a compound represented by formula IV or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for treatment of diseases caused by viruses, the viruses being HIV, HPV, EBV, IFV and/or coronaviruses. The poly ADP ribose polymerase inhibitor comprises a compound represented by formula III and/or a compound represented by formula IV or a pharmaceutically acceptable salt thereof, and can achieve a lower effective concentration for inhibiting viruses and a higher antiviral activity while ensuring low toxicity and high safety when being used in human bodies, so that in the application to the clinical treatment of diseases caused by coronaviruses, the present inhibitor can effectively inhibiting the viruses.

2-(PYRIDIN-3-YL)-1H-INDOLE DERIVATIVES AS INHIBITORS OF INTERACTION BETWEEN SPIKE AND ACE2 PROTEINS FOR THE TREATMENT OF RESPIRATORY VIRUS INFECTIONS

Resumen de: EP4818164A1

0001 The present invention relates to an indole derivative of formula (I) 3,3'-(pyridine-3,5-diylbis(5-methoxy-1H-indole-2,1-diyl))bis(N,N-dimethylpropan-1-amine) as inhibitors of interaction between Spike and ACE2 proteins for the treatment of infections due to respiratory viruses, such as e.g. SARS-CoV-1, SARS-CoV-2 or MERS CoV infections.

METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES

Resumen de: UA131281C2

The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).

COMPOSITIONS OF MRNA-ENCODED VIRUS-LIKE PARTICLES, COMPOSITIONS OF MRNA-LIPID NANOPARTICLES, AND METHODS FOR USE THEREOF

Resumen de: US20260295033A1

An immunogenic composition is described, comprising mRNA encoding polypeptides constituting a virus-like particle (VLP), and a pharmaceutically acceptable carrier. The polypeptides constituting the VLP comprise: a first polypeptide comprising a gag protein found in murine leukemia virus (MEV) having at least 95% identity with the amino acid sequence of SEQ ID NO: 1; and at least one additional polypeptide, which may comprise a protein of a virus, such as EB V, CMV, or coronavirus, for example a spike glycoprotein from a beta coronavirus such as SARS-COV-2, SARS-COV-1 or MERS-COV; or the at least one additional polypeptide may comprise a protein expressed by a cancer cell or tumour cell. A lipid nanoparticle composition is also described, which may comprise the VLPs. Methods of treatment or prevention of infection, such as from EBV, CMV, or coronavirus, or for treatment or prevention of cancer are described.

PROBE SET FOR NUCLEIC ACID TESTING OF SARS-COV-2 CORONAVIRUSES AND USES

Resumen de: US20260297692A1

The present invention discloses a probe set for nucleic acid testing of SARS-CoV-2 coronaviruses and uses. A crRNA sequence for nucleic acid testing of SARS-CoV-2 coronaviruses is any one of the following: LbucrRNA1, LbucrRNA2, LbucrRNA3 and LbucrRNA4 for an S gene, as well as N1crRNA and N2crRNA for an N gene of a mutant strain EG.5.1.1, with sequences shown in the sequence listing. Based on the ability of the LbuCas13a protein to cleave free RNAs and target specific RNA sequences, the present invention establishes an Cas13a-based immunochromatographic method for nucleic acid testing using a visual testing method based on colloidal carbon immunochromatographic test strips. The method enables rapid testing of SARS-CoV-2 coronaviruses within 90 min, providing a novel, easy and rapid testing method for disease prevention and control. Moreover, the method is simple to operate and does not require the assistance of large instruments and equipment.

CONSTRUCTS AND COMPOSITIONS FOR SARS-COV-2 VACCINES AND METHODS OF USE THEREOF

Resumen de: WO2026207328A1

A combined multi-antigen utilizing an immunogenic vector expressing a modified SARS-CoV-2 virus S, M and N protein S-C5 (Delta or Omicron), M-C5, and N-C5, epitopes thereof, compositions comprising same, and methods of use for general vaccination against SARS-CoV-2 virus.

SARS-CoV-2 immunodominant peptide constructs and uses thereof

Resumen de: AU2026230128A1

Abstract Provided herein are methods and compositions for the treatment and/or prevention of COVID-19 through the induction of an immune response against identified SARS-COV 2 immunodominant peptides. Abstract

METHOD FOR TREATING AND PREVENTING COVID-19

Resumen de: US20260294902A1

0000 A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4/ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.

IMMUNOGENIC COMPOSITION AND USES THEREOF

Resumen de: US20260295031A1

0000 The disclosure provides a composition comprising a feline coronavirus (FCoV) receptor binding domain peptide and a human severe acute respiratory syndrome coronavirus serotype 2 (SCoV2) receptor domain peptide and uses thereof.

VZV ANTIGEN VARIANT, NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Resumen de: EP4814118A1

0001 The present invention discloses a VZV antigen variant, a nucleic acid, a pharmaceutical composition, and uses thereof. The VZV antigen variant has a Y582G difference compared to the amino acid sequence shown in SEQ ID NO: 1; and/or, the VZV antigen variant has a deletion of positions 561-623, 569-623, or 574-623 compared to the amino acid sequence shown in SEQ ID NO: 1; and/or, the VZV antigen variant has a modification of the protein transmembrane domain and intracellular domain compared to the amino acid sequence shown in SEQ ID NO: 1, wherein the modification of the protein transmembrane domain and intracellular domain comprises replacing the transmembrane domain and intracellular domain of the original VZV antigen with the transmembrane domain of the SARS-CoV-2 Spike protein or the transmembrane domain of the influenza H protein. The VZV antigen variant has stronger immunogenicity than VZV antigens in the prior art, can achieve higher binding antibody titers, and has higher protective efficacy.

SMALL PEPTIDES FOR INHIBITING SARS-COV-2 SPIKE PROTEIN-AND LPS-INDUCED INFLAMMATION AND CYTOKINE PRODUCTION

Resumen de: WO2025111412A1

Small anti-inflammatory peptide for blocking NF-κB are disclosed herein. The peptides as well as compositions including the peptides can be administered to inhibit cytokine production and/or inhibit pulmonary inflammation in a subject in need. Particularly embodiments include administration to a subject suffering from coronavirus disease 2019 (COVID-19).

PHARMACEUTICAL DRY POWDER COMPOSITION AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS

Resumen de: US20260283946A1

The present invention provides a pharmaceutical dry powder composition for use in treating, preventing and/or amelio-rating viral infection in airways of a mammal, such as a human subject, said composition comprising micronized sodium salt as the main component and primary therapeutic agent. The present invention further provides a pharmaceutical composition for use in treating and/or ameliorating cough. The subject to be treated with the pharmaceutical composition may be infected with SARS-COV-2 and/or diagnosed with COVID-19 infection. The pharmaceutical composition is administered by dry powder inhalation.

BENZALKONIUM CHLORIDE FOR USE IN TREATING CONJUNCTIVITIS AND/OR COVID-19

Resumen de: US20260283984A1

Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.

POLYSACCHARIDE ADJUVANTS FOR USE IN PROTEIN-BASED OR RNA-BASED VACCINES

Resumen de: US20260284187A1

0000 Provided herein are adjuvantation systems comprising mannan (e.g., a plant mannan or a fungal manna) for use with Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus antigen or a nucleic acid encoding the Beta coronavirus antigen.

A viral vector and a vaccine composition comprising the vector

Resumen de: US20260284181A1

0000 The present invention provides a viral vector comprising, at an insertion site in the viral genome, a nucleic acid sequence encoding a modified extracellular domain of the SARS-CoV-2 spike protein, wherein said modified extracellular domain comprises an N-terminal signal peptide causing the spike protein to enter a secretory system in a host cell, wherein said modified extracellular domain comprises a C-terminal deletion of at least of heptad repeat 2 (HR2), transmembrane segment (TM) and cytoplasmic tail (CT) of the spike protein. The present invention also provides a vaccination composition comprising said viral vector.

PROPHYLAXIS AND TREATMENT OF CORONAVIRUS INFECTION

Resumen de: US20260284083A1

The present invention relates to the use of antagonists of tlr7-signalling for the treatment of COVID-19 patients, wherein the antagonists of tlr7-signalling are administered only after serovonversion. The invention also relates to a tlr agonist for use in the one-time prophylactic treatment of a subpopulation against an infection with a coronavirus, wherein the subpopulation is a collection of asymptomatic subjects in proximity to subjects of the population who show symptoms of infection.

IMMUNO-THERAPEUTIC CHEMICAL COMPOSITIONS AND USES THEREOF

Resumen de: US20260284056A1

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of ImmunoFolate.

REPLICATION-DEFICIENT SARS-COV-2 VACCINE STRAIN COMPRISING MUTATION IN N GENE AND USES THEREOF

Resumen de: WO2026197674A1

The present invention relates to a replication-deficient SARS-CoV-2 vaccine strain comprising a mutation in the N gene and uses thereof. More specifically, the present invention relates to a SARS-CoV-2 vaccine strain having five stop codons inserted into the N (nucleocapsid) gene of SARS-CoV-2, such that replication is impossible in cells in which the N gene is not trans-complemented, and uses thereof.

3CL protease Sars-Cov2 3CL-protease mutant a method of crystallizing the mutant and the use of the mutant

Resumen de: KR20260140403A

본 발명은 3CLpro 단백질의 변이체와 야생형 3CLpro 저해제로 알려진 화합물과 상기 변이체의 결합 복합체, 이의 결정화 방법, 및 이의 3차원 결정체에 관한 것으로서, 본 발명의 변이체 및 복합체의 활성부위와 3차원 결정 구조 정보를 제공한다. 본 발명의 3CLpro 변이체의 결정은 결정화 정도가 우수하고 X-선 분석이 용이하다. 이에, 본 발명은 상기 변이체 또는 복합체를 이용한 신규 3CLpro 억제제 스크리닝 방법을 제공하며, 이를 통해 개발된 3CLpro 억제제는 항바이러스제로 이용될 수 있다. 본 발명의 3CLpro 변이체는 기존에 보고된 Sars-cov2 바이러스, 코로나바이러스, 인간 코로나 및 엔터로바이러스의 3CLpro와 다른 활성화 부위 및 결합부위를 가진다. 따라서 본 발명은 백신에 내성을 갖는 돌연변이 바이러스 감염 질환 치료제 내지는 기존에 보고된 치료제 보다 강력한 치료 효능을 나타내는 약물 개발 플랫폼으로 이용될 것으로 기대된다.

TREATMENT OF VIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME

Resumen de: EP4810599A2

0001 The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).

MOBILE PURIFICATION DEVICE HAVING HEATED FILTER FOR KILLING BIOLOGICAL SPECIES, INCLUDING COVID-19

Resumen de: EP4810861A2

An apparatus is used with supplied power for treating air in an environment. A housing is mobile in the environment and has an intake and an exhaust. At least one prime mover disposed in the housing between the intake and the exhaust is operable to move the air in the environment through the housing from the intake to the exhaust. At least one ultraviolet light source disposed in the housing is connected in electrical communication with the supplied power and is configured to generate ultraviolet radiation in at least one a portion of the housing through which the moved air passes from the intake to the exhaust. At least one permeable barrier disposed in the housing is configured to impede the moved air flow therethrough up to an impedance threshold. The at least one permeable barrier is connected in electrical communication to the supplied power and being heated to a surface temperature.

MUTATED SPIKE PROTEINS AS VACCINES AGAINST SARS-COV-2

Resumen de: AU2025231994A1

The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein/hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.

ANALYTE SIGNATURES OF LONG COVID AND USES THEREOF

Resumen de: WO2026193026A1

The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).

END BINDING PROTEIN 3 INHIBITORY PEPTIDES AND METHODS OF USING THE SAME IN THE TREATMENT OF LUNG INJURY

Resumen de: WO2026192998A1

A peptide that blocks the interaction of microtubule-associated factor End Binding protein 3 with inositol 1, 4, 5-trisphosphate receptor 3 and calcium release from the endoplasmic reticulum, and methods of using the peptide to treat a disease or condition, in particular an inflammatory disease or condition of the lung including sepsis, inflammatory lung injury, pulmonary fibrosis, acute respiratory distress syndrome, or SARS-CoV-2 infection.

CYSTEAMINE FOR THE TREATMENT, MITIGATION AND PREVENTION OF CORONAVIRAL, E.G., SARS-CoV-2, INFECTIONS

Resumen de: US20260272861A1

Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.

SYSTEM FOR MINIMIZING RISK OF TRANSMISSION OF INFECTION

Resumen de: US20260274133A1

Disclosed herein are systems for minimizing the risk of transmission of SARS-COV-2 and/or other infectious diseases between individuals in close proximity to one another. Said systems may comprise a substantially transparent shield component, a chamber component, and a suctioning component. The systems of the present disclosure are intended to remove any SARS-COV-2 virus and/or other infectious agents that may be travelling within aerosols.

LIPOSOME, ESPECIALLY FOR USE IN THE TREATMENT OF COVID-19

Resumen de: WO2022098250A1

An object of the invention is a liposome preparation suitable for use in the treatment of COVID-19.

T CELL BROAD BETACORONAVIRUS VACCINE

Resumen de: WO2026185415A1

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the prophylactic or therapeutic treatment of an infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2.

PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM

Resumen de: US20260263473A1

In alternative embodiments, provided are pharmaceutical compositions and therapeutic combinations of drugs, including products of manufacture and kits, for treating, preventing or ameliorating (for example, decreasing the symptoms of, or decreasing the mortality of) a viral infection, for example, a coronavirus infection such as a COVID-19 or variant thereof, and methods for making and using same. In alternative embodiments, provided are products of manufacture and kits for delivering pharmaceutical compositions and therapeutic combinations of drugs as provided herein, for example provided are transdermal delivery devices such as patches that can have multiple compartments for delivering transdermally different drugs at the same time.

TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS

Resumen de: US20260263430A1

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

SYSTEM, APPARATUS, AND METHOD FOR VIRAL MONITORING IN EFFLUENT

Resumen de: US20260266815A1

A system for viral monitoring in effluent includes at least one graphene-based field-effect transistor and circuitry, wherein the circuitry is configured to repeatedly monitor and determine presence of SARS-CoV-2 (COVID virus) in the effluent. The circuitry is configured to apply a gate voltage and measure a conductance across each of the at least one graphene-based field-effect transistor, compare the measured conductance across each of the at least one graphene-based field-effect transistor to a threshold conductance, and determine whether levels of the COVID virus exceed a predetermined threshold in the effluent. If levels of the COVID virus exceed the predetermined threshold in the effluent, the circuitry is configured to remove at least a portion of the bound COVID virus from the proteins of the at least one graphene-based field-effect transistor.

METHODS OF TREATING FIBROSIS

Resumen de: US20260263460A1

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

PROTEIN AND VACCINE AGAINST INFECTION BY SARS-COV-2 OMICRON VARIANT STRAIN AND SUBTYPE THEREOF

Resumen de: US20260263587A1

The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-COV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-COV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-COV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-COV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-COV-2 Omicron mutant strain and subtype viruses thereof.

METHOD FOR TREATING COVID-19 INFECTION IN A HUMAN SUBJECT

Resumen de: US20260263510A1

0000 A method of treating a COVID-19 infection including administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The particles of the composition are monodisperse, and spherical, and have an average diameter of 70-100 nanometers (nm).

MULTI-OMIC PROFILING SIGNATURES FOR COVID-19

Resumen de: US20260265825A1

0000 A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.

REAGENTS AND METHODS FOR PREVENTING, TREATING OR LIMITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS INFECTION

Resumen de: US20260263588A1

Polypeptides and nucleic acids encoding the polypeptides are provided that include severe acute respiratory syndrome Co-V-2 (SARS-CoV-2) spike polypeptide receptor-binding domain (RBD) polypeptides that include at least one non-naturally occurring N-linked glycosylation motif in any of the residues 369-372, 388-390, 405-407, 417-419, 437-441, 477-479, 487-489 and 501-503, which are capable of multimerization and thus presenting multiple copies of the RBD to enhance the immune response generated when the polypeptide is administered to a subject.

METHODS OF TREATING FIBROSIS

Resumen de: AU2025233025A1

Described herein are methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF

Resumen de: US20260265350A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

METHOD FOR PREPARING 4-(2-(DIFLUOROMETHOXY)PHENYL)-5-METHYLTHIAZOL-2-AMINE, WHICH EXHIBITS PREDICTED ACTIVITY AGAINST THE SARS-COV-2 VIRUS

Resumen de: UA164235U

Method for preparing 4-(2-(difluoromethoxy)phenyl)-5-methylthiazol-2-amine: , which exhibits predicted activity against the SARS-CoV-2 virus, according to which a mixture of equimolar amounts of 2-bromo-1-(2-(difluoromethoxy)phenyl)propan-1-one and thiourea is boiled for three hours in propan-2-ol, cooled, filtered and suspended in 50 ml of saturated NaHCO3 solution, stirred for 5 hours, filtered, washed with water, crystallized from propan-2-ol.

METHOD FOR DETERMINING THE LEVEL OF RISK OF SEVERE COVID-19 DISEASE IN A PATIENT

Resumen de: WO2025080149A1

A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.

ASSAYS FOR THE EVALUATION OF SEASONAL COVID-INFLUENZA COMBINATION VACCINES

Resumen de: US20260259196A1

Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) from a subject that has been administered a an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus contains antibodies that inhibit influenza virus hemagglutinin (HA) glycoprotein hemagglutination activity, antibodies that neutralize SARS-COV-2 virus, antibodies that bind SARS-COV-2 spike protein, and/or antibodies that neutralize seasonal influenza virus. The methods include assaying a biological sample, where the biological sample is from a subject that has been administered an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus, and is not significantly affected by interference of analyte detection between the methods.

SARS-COV-2 Biomarkers for Predicting Severity of SARS-CoV-2 infectious disease

Resumen de: KR20260132653A

본 발명은 SARS-COV-2 바이러스 감염 질환의 중증도 예측용 바이오마커에 관한 것으로, SARS-COV-2 바이러스 감염 질환의 중증 환자 및 경증 환자에 대한 임상 데이터를 활용하여 cis-eQTM 분석을 통해 32종의 DNA 메틸화 마커 및 상기 DNA 메틸화 마커에 의해 차별적으로 발현되는 18종의 유전자 또는 단백질 마커를 제공한다.

ANTI-SARS-COV-2 SPIKE (S) IMMUNOASSAY AND METHODS OF USE THEREOF

Resumen de: US20260259220A1

0000 Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains IgA antibodies against SARS-CoV-2 S glycoproteins. The method includes contacting a biological sample with a SARS-CoV-2 S glycoprotein-coated surface, contacting the surface with a secondary antibody, and detecting the secondary antibody, where if a secondary antibody is detected, the sample contains IgA antibodies against the SARS-CoV-2 S glycoprotein. Assay substrates and kits for performing such methods are also disclosed.

COMPOSITIONS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING FROM A SARS-COV-2 INFECTION

Resumen de: US20260256871A1

0000 The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.

COVID-19 AND RESPIRATORY DISEASE VIRUS INFECTION MODELS USING LUNG ORGANOIDS

Resumen de: US20260259197A1

The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Resumen de: US20260256905A1

0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

SARS-CoV-2 Fc Recombinant adenovirus comprising SARS-CoV-2 derived receptor binding domain and antibody Fc region and uses thereof

Resumen de: WO2026182475A1

The present invention relates to a recombinant adenovirus comprising a SARS-CoV-2-derived receptor-binding domain and an antibody Fc region, and a use thereof, and provides: a polynucleotide comprising a SARS-CoV-2 spike-derived receptor-binding domain and an antibody Fc region; a recombinant adenovirus comprising the polynucleotide; and a vaccine composition for preventing SARS-COV-2 infection, comprising the recombinant adenovirus as an active ingredient.

USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION

Resumen de: EP4799624A2

Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising Pipendoxifene or analogues thereof (e.g., a compound of Formula (I), Formula (II), or Formula (III)) to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.

COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19

Resumen de: WO2025090605A1

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME

Resumen de: WO2023209177A1

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.

Nouveaux composés à base d’acides aminés modifiés comme inhibiteurs de la réplication du SARS-CoV-2, leurs formulations et applications

Resumen de: MA70856A1

Cette invention est relative à de nouveaux composés à base de lacide éthacrynique couplé avec des acides aminés modifiés comme lillustre la formule (I). Ces composés sont conçus pour le traitement du SARS-CoV-2, des pathologies liées à la COVID-19, ainsi que des maladies associées aux -coronavirus. Cette invention porte également sur leur application in vitro pour étudier l'inhibition de la réplication du SARS CoV2. De plus, cette invention inclut des compositions pharmaceutiques comprenant, comme principe actif, au moins un composé de la formule (I).

Methods and modified nucleosides for treating coronavirus infections

Resumen de: NZ802021A

Provided are methods for treating coronavirus infections by administering modified nucleosides, ester and amino acid ester prodrugs of nucleoside, their pharmaceutically acceptable salts, and drug combination thereof, of Formula (I). The compounds, combination, and methods provided are particularly useful for preventing, mitigating, or treating coronavirus infections or cytopathic effects resulting from the replication or reproduction of coronaviruses and their variants, including SARS-CoV-2.

Treatment of pathological fatigue with oxaloacetate

Resumen de: NZ801710A

The present disclosure relates to methods of treatment and compositions for treatment of Pathological Fatigue caused by injury or disease in the body. Pathological fatigue refers to physical and mental fatigue that is caused by viral infection, bacterial infection, trauma, disease, or genetic alteration that results in fatigue that is not improved by bed rest and may be worsened by physical or mental activity. Such pathologic fatigue occurs in myalgic encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) and other disorders such as such as post-COVID-19 fatigue, post-viral fatigue, fibromyalgia (FM), cancer, Parkinson’s Disease, other diseases and trauma as well as of combinations thereof. Related treatment methods and pharmaceutical compositions are also disclosed.

SARS-CoV-2 ANTIBODIES AND BISPECIFIC ANTIBODIES

Resumen de: US20260250363A1

0000 Provided herein are antibodies or antigen binding fragments thereof having a binding specificity for SARS-CoV-2 spike protein, and bispecific antibodies comprising a first and a second antigen binding region that bind to SARS-CoV-2 spike protein. Also provided herein are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, or bispecific antibodies.

RECOMBINANT HPV16 E6E7 ADENOVIRUS, VACCINE THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: WO2026174523A1

The present invention relates to the field of cancer immunotherapy technology, and specifically, to a recombinant HPV16 E6E7 adenovirus, a vaccine thereof, a method for preparing same, and use thereof. The present invention provides a recombinant HPV16 E6E7 adenovirus, comprising an HPV16 E6E7 antigen sequence and SARS-CoV-2 virus HR1 and HR2 region sequences. The recombinant HPV16 E6E7 adenovirus vaccine prepared by using the adenovirus, when used either alone or in combination with other anti-tumor drugs, can significantly inhibit the growth of tumors in cervical cancer and head and neck squamous cell carcinoma, and induce a significant cellular immune response in mice.

FUSION PROTEIN OF ULTRA-STABLE INTRACELLULAR ANTIBODY TARGETING PDIA3 AND USE THEREOF

Resumen de: WO2026175420A1

Provided are a fusion protein of an ultra-stable intracellular antibody targeting PDIA3 and the use thereof. The fusion protein comprises an antigen-binding peptide targeting PDIA3 and an intracellular stabilizing peptide. The antigen-binding peptide comprises a heavy chain variable region and a light chain variable region. By means of optimally designed intracellular stabilizing peptide and signal peptide sequences, the antibody can stably exist in cells and specifically localize to the endoplasmic reticulum. The fusion protein can effectively target and bind to the PDIA3 protein, significantly inhibit the expression levels of S proteins from human coronaviruses and capsid proteins from various non-enveloped viruses in cells, and regulate endoplasmic reticulum stress via protein-protein interactions on the ER of host cells, thereby promoting the degradation of the viral proteins and further effectively reducing the infectivity of the viruses.

MICRONEEDLE ARRAY PATCH FOR EXPRESSION OF THERAPEUTICS

Resumen de: WO2026178292A1

Microneedle patches or microneedle array patches (MAPs) offer a convenient method to intradermally deliver drugs and vaccines. Embodiments include MAPs that overcome the limitations of conventional MAPs. In aspects, the MAPs include (a) a base, (b) an adhesive region and (c) a plurality of needles on a surface of the base. The needles can comprise a medicament (e.g., a therapeutic or vaccine). In aspects, the medicament is a circular RNA vaccine that elicits an immune response against SARSCoV-2.

MULTI-PATCH VACCINES AND IMMUNOGENIC COMPOSITIONS, METHODS OF PRODUCTION AND USES THEREOF

Resumen de: US20260250326A1

0000 The present invention relates to a method for producing immunogenic compositions, such as vaccines, by identifying amino acid sequence of antigenic patches (Ag-Patches) from at least one proteome of a pathogen, derived from overlapping epitope clusters. In particular, the invention relates to the design of Multi-Patch Vaccines against viral, such as SARS-CoV-2, bacterial, fungi, parasite, pathogenic and non-pathogenic targets.

METHOD FOR TESTING DISEASED STATE OF VASCULITIS OR AGGRAVATION RISK OF COVID-19, TESTING KIT, COMPANION DIAGNOSTIC AGENT, AND TESTING MARKER

Resumen de: US20260251661A1

A method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject, (1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and/or (2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.

DEVICES AND RELATED METHODS FOR VENTILATION

Resumen de: EP4796155A2

Provided herein are devices and methods that relate to ventilation and respiration. In one embodiment, a ventilator device comprising a fluidic amplifier with one or more coaxially aligned components, where there are no internal moving components. In another embodiment, a device and related methods for treating a patient who needs ventilation such as after infection by the coronavirus Covid-19.

METHOD FOR OBTAINING ETHYL 2-{2-(5-BENZYL-1,3,4-OXADIAZOLE-2-YL)SULFANYLACETAMIDE}-4H,5H,6H-CYCLOPENTAbTHIOPHENE-3-CARBOXYLATE, WHICH EXHIBITS PREDICTED ACTIVITY AGAINST THE SARS-CoV-2 VIRUS

Resumen de: UA164073U

Method for obtaining ethyl 2-{2-(5-benzyl-1,3,4-oxadiazole-2-yl)sulfanylacetamide}-4H,5H,6H-cyclopentabthiophene-3-carboxylate, which exhibits predicted activity against the SARS-CoV-2 virus, wherein mixture of equimolar amounts of 5-benzyl-1,3,4-oxadiazole-2-thiol and ethyl ester of 2-(2-chloro-acetylamino)-5,6-dihydro-4H-cyclopentabthiophene-3-carboxylic acid is boiled in the presence of calcined K₂CO₃ under a reflux condenser for two hours in acetonitrile, while stirring. Mixture is then cooled, poured into ice water, precipitate is filtered, dried, and recrystallized from 2-propanol.

KYNURENINE: USEFUL BIOMARKER IN ACUTE COVID-19 AND LONG COVID

Resumen de: EP4266057A1

The invention relates to an in vitro method for the detection of inflammation caused by an acute COVID-19 infection, long COVID and/or PIMS, wherein the level of kynurenine in a body fluid is determined and wherein the value of kynurenine measured in the patient to be diagnosed is compared with the average value obtained from a comparable cohort of persons who do not suffer from said diseases, whereby the value of kynurenine in patients is increased.

Antiviral cyclic compounds

Resumen de: US20260242415A1

0000 The present invention relates to novel cyclic peptides. The peptides bind viral proteins, particularly a conserved site on the SARS-CoV-2 spike protein, and therefore the peptides can be useful for neutralizing SARS-CoV-2 variants. Accordingly, the invention also relates to medical use of the peptides.

BROAD-SPECTRUM BISPECIFIC ANTIBODY AGAINST NOVEL CORONAVIRUSES

Resumen de: US20260242448A1

The present disclosure provides a broad-spectrum bispecific antibody against novel coronaviruses, comprising a first targeting domain D1 targeting a first epitope of a SARS-CoV-2 RBD domain, and a second targeting domain D2 targeting a second epitope of the SARS-CoV-2 RBD domain. The bispecific antibody of the present disclosure has a broad-spectrum neutralizing activity and can effectively neutralize SARS-CoV-2 and various highly infectious and harmful SARS-CoV-2 variant strains, thus showing significant application value in the prevention, treatment, and/or detection of infections caused by novel coronaviruses.

ANTIVIRUS PROTEINS HAVING A KRINGLE 5 SUBUNIT

Resumen de: US20260242447A1

COVID-19 results from the infection of the SARS-CoV-2 virus and has spread quickly to literally infected the world. Although coronavirus spike proteins can recognize a broad range of host cell-surface proteins, inhibiting spike protein binding to a survival factor called GRP78 results in a significant reduction in SARS-CoV-2 attachment, entry and replication in lung and kidney cells. This inhibition is accomplished with a novel type of inhibitor that potently blocks the binding of SARS-CoV-2 spike protein and whole virus to surface-bound GRP78. These novel GRP78 inhibitors also down regulate cytokines (IL10, IL6), immune co-inhibitory checkpoint proteins (PD-L1, B7H3, B7H4), and up regulate immune co-stimulatory proteins (MHC-II, CD-86) resulting in the reduction of the immune suppressive nature of infected lung alveolar epithelial cells in vitro and in vivo. Finally, these novel GRP78 inhibitors inhibit the hyperfibrinolysis of infected lung cells by reducing the activation of plasmin on cell surfaces.

NOVEL CORONAVIRUS PROTECTIVE NASAL SPRAY, AND PREPARATION AND USE THEREOF

Resumen de: US20260242763A1

0000 A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.

BENZODIAZOCINE COMPOUND AS ANTIVIRAL AGENT AND PROCESS FOR PREPARATION THEREOF

Resumen de: WO2026172365A1

This study presents the synthesis of novel Benzodiazocine analogues and their potential as potent antiviral agents. Benzodiazocines, featuring an eight-membered fused bicyclic core, adhere to Lipinski's rule of five, ensuring drug-like properties. Structural modifications via Structure-Activity Relationship (SAR) enhanced their antiviral efficacy. In vitro assays, including cytotoxicity analysis and RT-qPCR-based studies, evaluated activity against SARS- CoV-2. Several analogues demonstrated promising antiviral potential, contributing to the ongoing pursuit of effective therapeutics against viral infections.

USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-COV-2

Resumen de: US20260240794A1

The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.

DIAGNOSTIC ASSAYS AND METHODS FOR DETECTING PATHOGENS

Resumen de: US20260242880A1

Provided are methods for co-extraction of DNA or RNA from two or more pathogens (such as Mycobacterium tuberculosis (Mtb) and SARS-CoV-2 (SC2)) in a sample. Also provided are assays for identifying a pathogen (such as Tuberculosis (TB)) directly from a sample.

COMPOSITION FOR PREVENTING OR TREATING CHEMOSENSORY DISORDER

Resumen de: US20260240922A1

0000 The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.

METHYLATION SIGNATURES OF PATHOGEN AND CHEMICAL EXPOSURES IN HUMAN CELLS

Resumen de: US20260242881A1

0000 Methods are provided for determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, human immunodeficiency virus type 1 (HIV-1), methicillin-susceptible Staphylococcus aureus (MSSA), or methicillin-resistant Staphylococcus aureus (MRSA), or has been exposed to an organophosphate (OP). Such methods include determining the measuring methylation status of numerous differentially methylated regions (DMRs) in the genomic DNA of particular PBMCs, such as those provided in Table 1, and in some examples also determining an amount of accessible chromatin in the isolated immune cells. Also provided are nucleic acid probes, arrays, solid supports (such a chip or nanosphere) and kits that can be used with such methods.

Core amino acid sequence group for targeted recognition of anti-SARS-Cov-2 neutralizing antibodies N-lgY-pAbs, and use thereof

Resumen de: AU2026210797A1

WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies 5 N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, and the designing of treatment targets and designing of vaccine targets. In the above amino acid sequence group, it is found that P272 in only one aa261-275 sequence of an S protein is a residue with a low-frequency mutation, and the remaining 19 sequences are 10 conservative amino acid sequences, do not contain the currently discovered virus mutation sites, and are highly conservative, which can effectively cope with the unfavorable situation of high-frequency mutation of SARS-CoV-2 at present. WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid 5 sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, a

ANTIMICROBIAL AND ANTIVIRAL, BIOLOGICALLY ACTIVE POLYMER COMPOSITES EFFECTIVE AGAINST SARS-COV-2 AND OTHER VIRAL, BACTERIAL AND FUNGAL TARGETS, AND RELATED METHODS, MATERIALS, COATINGS AND DEVICES

Resumen de: US20260240166A1

0000 Biologically active ion-exchange polymer salts are made by exchanging biologically active ionic agents onto organic ion exchange polymers. The activated polymers are uniquely surface active for use in a wide range of antibacterial, antifungal and antiviral coatings, materials, and devices, to minimize or prevent pathogen transmission and/or infection of a susceptible individual such as a patient in a hospital. The resultant coatings, materials, and devices are the foundation of a system enabling the construction of spheres of protection, for example to protect against transmission of COVID-19 (SARS-COV-2) coronaviruses and other viral and fungal pathogens in a clinical or institutional environment, for example hospitals, community institutions, cruise ships, and long-term care facilities. The activated ion-exchange polymer salts are process stable, allowing size reduction and formulation of the resulting powders into bulk polymers or polymer precursors to produce stable, biologically active polymer composites, including antimicrobial and antiviral polymer composites.

LUMINOL FOR THE PROPHYLAXIS AND THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION

Resumen de: WO2022117221A1

The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.

Improved form of a liposomal trap inhibitor of SARS-CoV-2 infection

Nº publicación: PL451191A1 17/08/2026

Solicitante:

ACELLMED SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA [PL]
ACELLMED SP\u00D3\u0141KA Z OGRANICZON\u0104 ODPOWIEDZIALNO\u015ACI\u0104

Resumen de: PL451191A1

Przedmiotem zgłoszenia jest liposomowy preparat, do stosowania w leczeniu COVID-19.